[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tuberous-sclerosis-complex-tsc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tuberous-sclerosis-complex-tsc":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,79,112,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":34,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100638972","periodontal-disease-in-rare-renal-disorders-perio-ra-re-100638972",false,"NCT07575347","Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)","Periodontal Inflammation in Rare Renal Disorders - A Cross-Sectional Controlled Observational Study Assessing the Burden and Phenotypes of Periodontal Disease","PERIO-RA-RE","Inclusion Criteria:\n\n* Age ≥18 years\n* Ability to provide written informed consent\n* At least 10 natural teeth present\n* Belonging to one of the predefined study groups:\n\n  1. Alport syndrome (genetically or clinically confirmed)\n  2. Fabry disease (enzymatically or genetically confirmed)\n  3. Tuberous sclerosis complex (according to established clinical or genetic criteria)\n  4. Systemic lupus erythematosus defined according to the 2019 EULAR\u002FACR or SLICC 2012 classification criteria, with renal involvement defined by at least one of the following: \\[1\\] Biopsy-proven lupus nephritis, \\[2\\] Persistent proteinuria (\\>0.5 g\u002Fday or equivalent), \\[3\\] Active urinary sediment (hematuria and\u002For cellular casts) consistent with lupus nephritis\n  5. Chronic kidney disease (CKD) of non-rare etiology: defined according to KDIGO criteria (eGFR \\\u003C60 ml\u002Fmin\u002F1.73 m² and\u002For markers of kidney damage)\n  6. Individuals without CKD, recruited from clinical or dental care settings as non-CKD controls\n\nExclusion Criteria:\n\n* Periodontal treatment within the last 6 months\n* Antibiotic therapy within the last 4 weeks\n* Pregnancy\n* Conditions precluding periodontal examination\n* Inability to comply with study procedures","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the burden and phenotypic spectrum of periodontal disease in patients with rare kidney disorders (such as Alport syndrome, Fabry disease, and tuberous sclerosis complex) and systemic lupus erythematosus (SLE), compared with chronic kidney disease (CKD) controls and population controls.\n\nThis is a cross-sectional, case-control observational study. Participants will undergo a single structured evaluation including a full-mouth periodontal examination, a clinical questionnaire, and collection of relevant clinical and nephrological data.\n\nThe primary objective is to compare the prevalence of periodontitis across study groups. Secondary objectives include characterization of periodontal disease severity, prevalence of gingivitis and xerostomia, and identification of disease-specific oral phenotypes.\n\nExploratory analyses will assess associations between periodontal disease and clinical variables such as kidney function, proteinuria, and immunosuppressive exposure.",[25,26,27,28,29,30,31,32,33],"Periodontal Disease","Periodontitis","CKD","Chronic Kidney Disease","Alport Syndrome","Fabry Disease","Lupus or SLE","Tuberous Sclerosis Complex (TSC)","Systemic Lupus Erythematosus (SLE)",[25,26,27,35,36,37,32,28],"Rare Kidney Diseases","Alport syndrome","Systemic Lupus Erythematosus","RECRUITING","2026-06-24",{"date":41,"type":42},"2026-06-26","ACTUAL",{"date":44,"type":42},"2026-05-04",{"date":46,"type":21},"2027-12-31",{"name":48,"class":49},"Stefan Lujinschi","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":50},"100623948","phase-3-treatment-with-full-spectrum-cannabis-extract-of-refractory-epilepsy-associated-with-tuberous-sclerosis-complex-tsc-100623948","NCT07403266","Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)","Spectrum","Inclusion Criteria:Patients of any sex between 2 and 65 years of age (both included) Diagnosis confirmed by the TSC investigator (by clinical criteria and\u002For genetic study).\n\nRefractory epilepsy secondary to TSC, defined as that not responding successfully to traditional AEDs (2 or more), ketogenic diet, vagal nerve stimulator, and\u002For whose patients are not candidate for epilepsy surgery or persist with seizures after surgery.\n\nPatients with a minimum of 4 epileptic seizures or more within 4 weeks prior to the initiation of the assigned treatment in the trial, with observable external signs (loss of consciousness or motor component).\n\nStability in AEDs doses, and in ketogenic diet\u002Fprogramming of the device associated with the vagal nerve stimulator with no changes for at least 4 weeks prior to the initiation of the assigned treatment.\n\nPatients who are in treatment with 3 or less AEDs at the time of signing the informed consent. For the purposes of assessing eligibility, Clobazam will not be counted as AED Willingness by patients or caregivers\u002Ffamily members (in case of patients who are minors or under legal guardianship) to complete the seizure diary.\n\nIn case of women of child-bearing age, for safety, those who agree to follow the required contraceptive measures from the signing of the informed consent until three months after stop the intake of the investigational medicinal product.\n\nPatients who have signed the informed consent either by themselves or through a legal representative.\n\n\\-\n\nExclusion Criteria:Patients who are receiving treatment on corticoids at the time of signing the informed consent.\n\nPregnancy. Breastfeeding women To have participated in another clinical trial, unless at least 5 half- lives of the investigational product have elapsed, or 12 weeks, if it is a product with cannabis oil.\n\nPatients who have received products with cannabis oil in the last 12 weeks. Patients who did not correctly follow the AED treatment in the 4 weeks prior to the intervention assigned in the trial.\n\nPatients who changed medication or AED dose, ketogenic diet, or the vagal stimulator during the 4 weeks prior to the initiation of the intervention assigned in the trial.\n\nCardiac, renal, and hepatic failure, pancreatic insufficiency, or hematologic dysfunction with values above the normal limits of creatinine and urea; values 2 times the normal limits of transaminases, lipases, and serum amylase; platelets \\\u003C 80000\u002Fmm3, and white blood cell count \\\u003C3000\u002Fmm3.\n\nUncontrolled severe medical condition such as: hepatic disease, increased bilirubin levels more than twice the normal limit, cirrhosis, chronic hepatitis (hepatitis B or C), uncontrolled diabetes (defined as blood glucose \\>150 mg%), (chronic or acute) active infections or uncontrolled severe infections, or active bleeding.\n\nPatients or family\u002Fcaregivers (in case of patients who are minors or under legal guardianship) who does not agree to comply with the requirements and trial visits or present a high risk of non-compliance with the protocol, according to the treating physician.\n\nAllergy to any of the components of the investigational medicinal product\u002Fplacebo.\n\nFamily (considering only first-degree blood relatives) or personal history of schizophrenia.\n\nPersonal history of suicide attempts.\n\n\\-","2 Years","65 Years",{"count":61,"type":21},84,"INTERVENTIONAL",[64],"PHASE3","1\\. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2. To assess the safety of the treatment with YCJ-01 in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex.",[32],[68],"Refractary Epilepsy","2026-02-04",{"date":71,"type":42},"2026-02-11",{"date":73,"type":42},"2024-06-01",{"date":75,"type":21},"2027-06",{"name":77,"class":78},"Oils4Cure","INDUSTRY",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":62,"phases":88,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":50},"100621352","phase-1-sapu003-in-advanced-mtor-sensitive-solid-tumors-100621352","NCT07369505","Sapu003 in Advanced mTOR-sensitive Solid Tumors","A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane)","Inclusion Criteria:\n\n1. Sex and Age: Patients must be ≥ 18 years of age at the time of informed consent.\n\n   * Cohort A (HR+\u002FHER2- breast cancer): Eligible patients must be postmenopausal women, defined as women ≥ 18 years of age with amenorrhea for ≥ 12 consecutive months without another pathophysiological cause.\n   * Cohort B (RCC, NETs, TSC-associated tumors, HCC): Eligible patients include both male and female adults with advanced disease.\n2. Cohort A HR+\u002FHER2- Breast Cancer:\n\n   Eligible patients must meet all of the following:\n   * Has histologically or cytologically documented advanced (metastatic or unresectable) hormone receptor-positive, HER2 negative breast cancer (advanced HR+ BC)\n   * Has stage IV or locally advanced breast cancer per the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, Seventh Edition;\n   * Has failed any combination endocrine therapy or relapse within 6 months of adjuvant chemotherapy for metastatic or locally advanced disease. Prior therapy should have included a non-steroidal aromatase inhibitor unless clinically contraindicated;\n   * Has agreed to participate in the study and signed the informed consent form prior to participation in any study activities.\n3. Cohort B Other Advanced mTOR-Sensitive Solid Tumors:\n\n   Eligible patients must meet all of the following:\n   * Has histologically or cytologically confirmed advanced (metastatic or unresectable) disease in one of the following tumor types:\n\n     * Renal Cell Carcinoma (RCC)\n     * Neuroendocrine Tumors (NETs)\n     * Tuberous Sclerosis Complex (TSC)-associated tumors\n     * Hepatocellular Carcinoma (HCC)\n   * Has disease that is measurable and\u002For evaluable per RECIST v1.1 (or relevant criteria, if applicable).\n   * Has progressed on or is intolerant to at least one prior line of standard therapy appropriate for the specific tumor type, unless no effective standard therapy exists.\n   * Has agreed to participate in the study and signed the informed consent form prior to participation in any study activities.\n4. Patients must be on stable doses of metformin or statin\n5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n6. Life expectancy ≥ 3 months\n7. Hematology\u002Fchemistry: Patient has adequate hematological, renal, and hepatic function as defined by the following Screening laboratory values obtained within 7 days prior to randomization and assessed based on local labs (patients should not have received a transfusion within 7 days before the Screening laboratory assessments):\n\n   * Absolute neutrophil count (ANC) ≥ 2,000 cells\u002Fmm3 (2 x109\u002FL)\n   * Platelet count ≥ 100,000 cells\u002Fmm3 (100x109\u002FL)\n   * Hemoglobin≥ 9 g\u002FdL\n   * Serum creatinine≤ 1.5 x the upper limit of normal (ULN)\n   * Total bilirubin ≤1.5 x ULN or direct bilirubin ≤1 x ULN for patients with total bilirubin levels \\> 1.5 ULN\n   * AST (SGOT) \u002F ALT (SGPT) ≤ 2.5 x ULN (≤5 x ULN for patients with metastases.)\n   * GFR ≥ 50 mL\u002Fmin\u002F1.73m2 by the CKD-EPI or MDRD formulas.\n8. All other clinical laboratory values deemed as normal or not clinically significant by the Principal Investigator\u002FSub-Investigator.\n9. Breastfeeding: Patients must be non-lactating. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding must be discontinued prior to the first dose of study drug.\n10. Female patients of reproductive potential to avoid becoming pregnant and to use effective contraception during the study and for 8 weeks after the last dose. Male patients with female partners of reproductive potential to use effective contraception during the study and for 4 weeks after the last dose.\n11. Able and willing to adhere to all protocol requirements and study procedures throughout the course of the study.\n12. Ability to comprehend and be informed of the nature of the study, as assessed by study clinic staff\n\nExclusion Criteria:\n\n1. Patients with a history of other malignancies, except for adequately treated non-melanoma skin cancer, curatively treated in-situ carcinoma of the cervix, curatively treated in-situ carcinoma of the breast, or other solid tumors curatively treated with no evidence of disease for \\> 5 years.\n2. Patients who have not completely recovered from any toxicities from previous chemotherapy, hormone therapy, immunotherapy, target therapy, or radiotherapies ≥ Grade 1 per NCI CTCAE version 5.0, with the exception of alopecia.\n3. Patients who have received any of the following treatments within the specified timeframes prior to screening:\n\n   * Prior chemotherapy within 30 days prior to screening (42 days for mitomycin C or nitrosoureas).\n   * Prior immunotherapy, prior anti-tumor hormonal therapy (for breast cancer patients), and prior radiotherapy within 30 days prior to screening.\n   * Radiotherapy is not allowed during study. Administration of other chemotherapy, immunotherapy, or anti-tumor hormonal therapy during the study is not allowed.\n4. Patients had major surgery within 30 days prior to randomization, or patients have not recovered from prior major surgery.\n5. Sensory \u002F Peripheral neuropathy of \\> Grade 1 per NCI CTCAE version 5.0 at Screening.\n6. Patients with active brain metastases. Patients with treated brain metastases are eligible provided they have no evidence of active brain disease and are off of definitive therapy (including steroids) at least 3 months prior to randomization.\n7. Known history or presence of any clinically significant disease or condition other than cancer unless determined as not clinically significant by the Principal Investigator\u002FSub-Investigator. This includes, but is not limited to, the following: hepatic, renal\u002Fgenitourinary, gastrointestinal (e.g., intra-abdominal inflammation), cardiovascular (e.g., congestive heart failure, ventricular arrhythmia, myocardial infarction, unstable angina pectoris), cerebrovascular, pulmonary (e.g., interstitial lung disease), endocrine, immunological, musculoskeletal, neurological, psychiatric, dermatological, or hematological (e.g., bleeding diathesis or coagulopathy).\n8. History of difficulty with donating blood or difficulty in accessibility of central line.\n9. Known history or presence of:\n\n   * Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C (serology to confirm absence is required within 7 days prior to randomization and assessed based on local labs);\n   * Alcohol abuse or dependence within one year prior to randomization;\n   * Drug abuse or dependence (marijuana, amphetamines, barbiturates, cocaine, opiates and benzodiazepines);\n   * Hypersensitivity or idiosyncratic reaction to everolimus, other rapamycin derivatives or its excipients\n   * Severe allergic reactions (e.g., anaphylactic reactions, angioedema).\n10. Patients may not participate in any other clinical protocol or investigational trial that involves administration of experimental therapy and\u002For the use of investigational devices with therapeutic intent within 30 days prior to randomization and while enrolled in this study. Caution is recommended when administering Sapu003 and concomitantly with known substrates, PgP inhibitors, inhibitors, and inducers of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4.\n11. Use of any strong inhibitors of cytochrome P450 (CYP) enzymes (e.g., fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (e.g., barbiturates (phenobarbital), carbamazepine, phenytoin and rifampin), in the previous 14 days before randomization until the last blood draw in the study.\n12. Acute active infection requiring antibiotics, antiviral agents, or antifungal agents within 14 days prior to randomization\n13. Pregnant or lactating women.",{"count":87,"type":21},27,[89],"PHASE1","This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced mTOR-sensitive solid tumors (HR+\u002FHER2-negative breast cancer, renal cell carcinoma \\[RCC\\], neuroendocrine tumors \\[NETs\\], tuberous sclerosis complex \\[TSC\\]-associated tumors, and hepatocellular carcinoma \\[HCC\\]).",[92,93,94,32,95],"Breast Cancer Metastatic","Renal Cell Carcinoma (RCC)","Neuroendocrine Tumors","Hepatocellular Carcinoma (HCC)",[97,98,99,93,100,32,95,101,102],"Sapu003","Everolimus for Injection","mTOR-Sensitive Solid Tumors","Neuroendocrine Tumors (NETs)","everolimus","HR+\u002FHER2-negative breast cancer","2026-01-17",{"date":105,"type":42},"2026-01-27",{"date":107,"type":42},"2025-12-15",{"date":109,"type":21},"2026-12",{"name":111,"class":78},"SAPU NANO (US) LLC",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":119,"targetDuration":4,"studyType":62,"phases":121,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":138,"locationsCount":140},"100615023","phase-1-safety-tolerability-and-pharmacokinetics-of-svg103-paxalisib-in-focal-cortical-dysplasia-type-ii-fcd-ii-tuberous-sclerosis-complex-tsc-or-hemimegalencephaly-hme-100615023","NCT07287202","Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)","An Open-Label Phase 1b\u002F2a Study to Evaluate the Safety and Tolerability of Oral SVG103 (Paxalisib) in Adults With Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME), Followed by Long-Term Treatment","Key Inclusion Criteria:\n\n1. Participants diagnosed with:\n\n   * FCD-II: diagnosis of FCD Type II based on clinical symptoms and confirmed by a positive magnetic resonance imaging (MRI) or histological\u002Fpathological analysis of brain tissue, or\n   * TSC: diagnosis of TSC by either clinical or genetic diagnostic criteria as documented in the participant's medical record, or\n   * HME: Definitive HME confirmed with MRI.\n2. Male or female between the ages of 18 and 65 years of age (inclusive).\n3. History of failure to control seizures despite at least 2 ASMs at appropriate dosages and duration of treatment.\n4. Participants must have experienced at least 8 countable seizures per month for 2 of the 3 months as documented in historical seizure diaries before the baseline period.\n\n6\\. If participants are on a ketogenic or modified atkins diet, that the regimen can remain unchanged throughout the study, in the opinion of the investigator.\n\n7\\. Participants with Neurostimulation devices (i.e. Vagus Nerve Stimulation (VNS), Responsive Neuro Stimulation (RNS), Deep Brain Stimulation (DBS) who meet all of the following conditions:\n\n* The device has been implanted for ≥1 year prior to the screening visit.\n* The settings must have remained constant for 3 months prior to the screening visit and can remain constant throughout the study, in the opinion of the investigator.\n* The battery is expected to last throughout the study. 8. A participant\u002Fcaregiver or LAR willing to give written informed consent, after being properly informed of the nature and risks of the study and prior to engaging in any study-related procedures.\n\nKey Exclusion Criteria:\n\n1. Clinically significant hepatic, renal, pulmonary, gastrointestinal, neurological (other than epilepsy; HME; TSC; FCD-II), autoimmune, immunological, infections, hematological, malignant conditions that may interfere with or impact the participation in the study or study conduct, as determined but the investigator or sponsor.\n2. Immunocompromised participants, defined as acquired immune deficiency syndrome (AIDS), cancer, malnutrition, and certain genetic disorders or undergoing treatment with anticancer drugs, radiation therapy, and stem cell or organ transplant.\n3. Participants who have an active central nervous system (CNS) infection, demyelinating disease, degenerative neurological disease, or CNS disease deemed progressive as evaluated by brain imaging (magnetic resonance imaging \\[MRI\\]).\n4. Participants being considered for brain surgery during the study or has undergone brain surgery within 6 months prior to screening visit for epilepsy or any other reason.\n5. Participants with HbA1c levels ≥9.0%, or with hyperglycemia or diabetes requiring insulin therapy, or significant uncontrolled hyperglycaemia or diabetes mellitus that would compromise patient safety, as determined by the investigator.\n6. Participants with active pneumonitis that are clinically symptomatic.\n7. Participants with a history of myocardial infarction or coronary artery disease or clinically significant ECG abnormality.\n8. Participants who have clinically significant hepatic, renal and blood laboratory values at baseline period.\n9. Participants with known sensitivity or allergy to any component in the investigational product(s) (microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and colloidal silicon dioxide).",{"count":120,"type":21},15,[89,122],"PHASE2","This is a multinational, open-label, single-arm trial of adjunctive SVG103 (paxalisib) treatment in adults with FCD-II, TSC, and HME.",[125,32,126],"Focal Cortical Dysplasia","Hemimegalencephaly",[128,129,130],"FCD-II","TSC","HME","NOT_YET_RECRUITING","2025-12-22",{"date":134,"type":42},"2025-12-23",{"date":136,"type":21},"2026-03",{"date":75,"type":21},{"name":139,"class":78},"Sovargen",2,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":150,"conditions":151,"keywords":152,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":50},"100574847","observational-retrospective-multicenter-nonprofit-study-on-the-prevalence-of-renal-involvement-in-pediatric-patients-with-tuberous-sclerosis-100574847","NCT06764602","Observational, Retrospective, Multicenter, Nonprofit Study on the Prevalence of Renal Involvement in Pediatric Patients With Tuberous Sclerosis","Inclusion Criteria:\n\n* Patients of either sex under the age of 17 years at the time of last observation (06\u002F30\u002F2021);\n* Patients clinically evaluated in an outpatient or inpatient setting during 01\u002F01\u002F2018- 30\u002F06\u002F2021 with a diagnosis of TSC;\n* Informed consent signed by parent or legal guardian.\n\nExclusion Criteria:\n\n* Patients older than 18 years of age;\n* Patients with other phacomatoses.","17 Years",{"count":149,"type":21},80,"Observational, retrospective, multicenter, nonprofit study on the prevalence of renal involvement in pediatric patients with tuberous sclerosis.",[32],[153,154,155],"Tuberous Sclerosis Complex","Nephropathy","Children","2025-01-07",{"date":158,"type":42},"2025-01-08",{"date":160,"type":42},"2021-07-01",{"date":162,"type":21},"2025-12-31",{"name":164,"class":49},"IRCCS Azienda Ospedaliero-Universitaria di Bologna"]